The National Institutes of Health has awarded approximately $53 million in annual funding over the next five years to 10 research organizations in a continued effort to find a cure for HIV. UNC-CH is among the recipients.
Read More
Ed Browne, PhD, assistant professor of medicine, is the principal investigator of a $4-million, 5-year study of the role of cannabis use in HIV latency – one of the main barriers toward curing people with the infection.
Read More
U.S. regulators have approved the first long-acting drug combo for HIV, monthly shots that can replace the daily pills now used to control infection with the AIDS virus.
Read More
ViiV Healthcare, which has a major presence in RTP, has secured European Union approval for its once-a-month treatment of HIV, offering an alternative to daily care.
Read More
The HIV Prevention Trials Network has won a seven-year funding agreement with the US National Institutes of Health, the latest agreement in a series of awards dating back more than a decade.
Read More
An injectable drug from ViiV Healthcare has proved to be much more effective in preventing HIV among women than a currently daily pill treatment, ViiV announced early Monday.
Read More
After a five-month battle with leukemia, the first known person to be cured of HIV has died of cancer, according to the International AIDS Society.
Read More
The public-private collaboration provides continued funding for HIV Cure Center and Qura Therapeutics, the joint venture that brings academic and pharmaceutical research scientists together .
Read More
A “major step” toward a possible cure for HIV with a technique that targets the virus as it lays dormant in people receiving treatment thus escaping being attacked by current therapy.
Read More
